Our team aims to develop tools to fight against multidrugresistant bacteria emergence. Our strategy is based on global approaches to decipher circulation of microorganisms in the environnement, elucidate their modes of transmission and understand their pathogenicity in Humans. Our research is focused on 2 families of bacteria: (i) The mycobacteria, with the example of Mycobacterium ulcerans, the causative agent of Buruli ulcer and (ii) the Enterobacteriaceae, for which antibiotic resistant is a major public concern.
(i) Buruli ulcer or Mycobacterium ulcerans is an emerging neglected tropical disease and the third mycobacterial disease in the world after tuberculosis and leprosy. This debilitating cutaneous disease is mainly diagnosed in West and Central Africa, where the children are the most affected. The aim of our team is to decipher the pathophysiology of this disease and to understand the biology of M. ulcerans bacilli by developing integrated and comprehensive approaches. In this context, we have developed several lines of research linked with WHO priorities. Our projects are always undertaken with our collaborators working in endemic areas in Africa allowing concrete actions such as the improvement of patient care.
(ii) Bacterial resistance to antibiotics is a major public health concern. Concerning Enterobacteriaceae, the problem is even more important that some bacteria can be resistant to all the antibiotics available for infection treatments. Our research topic can be divided in 3 axes: improving our knowledge about the development of theses pathogen reservoirs for limiting their dissemination, better understanding the evolution from asymptomatic colonization to infection, and assessing the effectiveness of new strategies of decolonization and treatment. In this context, all our projects are elaborated with some perspectives of practical outcomes in terms of prevention and treatment.
L. Marsollier, DR Inserm
E. Marion, CR, Inserm (leader)
M. Eveillard, PU-PH
M. Kempf, MCU-PH
M. Robbe-Saule, IR CDD Univ
A. Durand, IE CDD Inserm
L. Esnault, AI CDD Inserm
V. Dubee, chef de clinique
H. Pailhories, Assistant hospitalier
A. Pouchin, Doctorante
M. Foulon, Doctorante
Biology of M. ulcerans :
Marion E, Jarry U, Cano C, Savary C, Beauvillain C, Robbe-Saule M, Preisser L, Altare F, Delneste Y, Jeannin P, Marsollier L. FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer. Journal of Immunology. 2016.
Marion E, Song OR, Christophe T, Babonneau J, Fenistein D, Eyer J, Letournel F, Henrion D, Clere N, Paille V, Guérineau NC, Saint André JP, Gersbach P, Altmann KH, Stinear TP, Comoglio Y, Sandoz G, Preisser L, Delneste Y, Yeramian E, Marsollier L, Brodin P. Mycobacterial toxin induces analgesia in Buruli ulcer by targeting the angiotensin pathways. Cell. 2014.
Marion E, Ganlonon L, Claco E, Blanchard S, Kempf M, Adeye A, Chauty A. Establishment of quantitative PCR (qPCR) and culture laboratory facilities in a field hospital in Benin: 1-year results. Journal of Clinical Microbiology. 2014.
Marion E, Obvala D, Babonneau J, Kempf M, Asiedu KB, Marsollier L. Buruli ulcer disease in Republic of the Congo. Emerging Infectious Disease. 2014.
Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundoté A, Cottin J, Ladikpo T, Ruf T, Ji B. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clinical Infectious Diseases. 2011.
Enterobacteria and resistances:
Coron N, Pavlickova S, Godefroy A, Pailhoriès H, Kempf M, Cassisa V, Marsollier L, Marion E, Joly-Guillou ML, Eveillard M. Mouse model of colonization of the digestive tract with Acinetobacter baumannii and subsequent pneumonia. Future Microbiology. 2017.
Mahieu R, Cassisa V, Godefroy A, Joly-Guillou ML, Eveillard M. Effect of faecal microbiota transplantation on mouse gut colonization with carbapenemase-producing Escherichia coli. Journal of Antimicrobial Chemotherapy. 2017.
Eveillard M, Ruvoen N, Lepelletier D, Fradet S, Couvreur S, Kempf M, Magras C. Integration of microbiology and infectious disease courses in an interdisciplinary training programme (Master level) centred on the “One world, one health” WHO concept. FEMS Microbiology Letters. 2016.
de Breij A, Eveillard M, Dijkshoorn L, van den Broek PJ, Nibbering PH, Joly-Guillou ML. Differences in Acinetobacter baumannii strains and host innate immune response determine morbidity and mortality in experimental pneumonia. PLoS One. 2012.
Eveillard M, Soltner C, Kempf M, Saint-André JP, Lemarié C, Randrianarivelo C, Seifert H, Wolff M, Joly-Guillou ML. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. Journal of Infection. 2010.